1. Effects of isomeric 2-(Arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cells

   • Christopher A. Carter
   • Kenneth W. Bair

   Preclinical Studies Pages: 125 - 136

2. Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065

   • Li H. Li
   • Robert C. Kelly
   • Thomas F. DeKoning

   Preclinical Studies Pages: 137 - 148

3. Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro

   • De-Lin Du
   • Donna A. Volpe
   • Martin J. Murphy Jr.

   Preclinical Studies Pages: 149 - 157

4. Pharmacokinetics of 2′,3′-dideoxyadenosine in dogs

   • M. Guillaume Wientjes
   • Michael E. Placke
   • Joseph E. Tomaszewski

   Preclinical Studies Pages: 159 - 168

5. A novel N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to Adriamycin

   • Catherine A. O'Brian
   • Nancy E. Ward
   • Dominic Fan

   Preclinical Studies Pages: 169 - 179

6. Toxicity trials of amsacrine (AMSA) and etoposide +/− azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study

   • C. Philip Steuber
   • Tate Holbrook
   • Jeffrey Krischer

   Clinical Studies Pages: 181 - 184

7. Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV²) in relapsed and refractory lymphomas

   • John P. Crown
   • Subhash Gulati
   • Joseph Bertino

   Clinical Studies Pages: 185 - 186

8. Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer

   • James R. Rigas
   • Mark G. Kris
   • Linda D. Marks

   Clinical Studies Pages: 187 - 190

9. Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy

   • Jacob B. Green III
   • Stephanie Green
   • Darryl L. Wallace

   Clinical Studies Pages: 191 - 193

10. Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors

    • Sarah A. Taylor
    • John Crowley
    • Jerry T. Guy

    Clinical Studies Pages: 195 - 197

11. Phase I studies of trimetrexate using single and weekly dose schedules

    • Susan D. Huan
    • Sewa S. Legha
    • Irwin H. Krakoff

    Clinical Studies Pages: 199 - 206

12. A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus

    • Robert E. Slayton
    • John A. Blessing
    • Barrie Anderson

    Clinical Studies Pages: 207 - 208

13. Working conference on biomodulator and chemotherapy combination therapies

    • Thomas D. Brown
    • Malcolm S. Mitchell
    • Geoffrey R. Weiss

    Meeting Report Pages: 209 - 214

14. Announcement

    Announcement Pages: 215 - 215